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ABSTRACT: This study was undertaken to per-
form a systematic review and meta-analysis of studies of
mortality in Parkinson’s disease (PD) and to investigate
which factors were associated with mortality. We con-
ducted comprehensive searches of studies reporting a
ratio of mortality in PD versus controls, descriptive sur-
vival measures, or factors predicting survival; assessed
study quality; and extracted relevant data. Descriptive
analysis, meta-analysis, and meta-regression were per-
formed as appropriate. Eighty-eight studies were
included in the review with variable study methods and
quality. Almost all studies reported increased mortality in
PD (vs. controls), with mortality ratios ranging from 0.9 to
3.8, with major between-study heterogeneity. Inception
cohorts were more consistent with a pooled mortality
ratio of approximately 1.5. Inception cohorts, measure-
ments at longer follow-up duration, and older study
recruitment year were associated with lower mortality
ratios, but these findings were not robust in sensitivity
analyses. Within studies, mortality ratios increased over
time. No robust evidence was found that mortality has
decreased after the introduction of levodopa (L-dopa).
On average, PD survival reduced by approximately 5%
every year of follow-up, although there was significant
heterogeneity. In post-mortem studies, mean duration
until death ranged from 6.9 to 14.3 years. Increasing age
and presence of dementia were most commonly associ-
ated with increased mortality. Parkinson’s disease is
associated with increased mortality, but major heteroge-
neity is seen in estimates of mortality, which is probably
explained by variable methodology and patient selection.
Individual-patient-data meta-analysis of high-quality
inception studies with long-term follow-up would be the
optimal way to investigate the factors influencing mortal-
ity. VC 2014 The Authors. Movement Disorders published
by Wiley Periodicals, Inc. on behalf of International Par-
kinson and Movement Disorder Society.
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Despite major advances in the understanding of its
pathophysiology and genetics, many aspects of the
prognosis of Parkinson’s disease (PD) remain unclear.
Improved understanding of PD prognosis would allow
better information and perhaps tailored treatment to
be given to patients and caregivers, improved health-
service planning, and improved clinical trial design.
Knowledge of predictors of poor prognosis may enable
individually tailored predictions and allow targeting of
treatments, particularly if this information is incorpo-
rated into a prognostic model.
One important aspect of PD prognosis is mortality,
which has been reviewed nonsystematically in several
papers.1-5 These showed generally increased but mark-
edly heterogeneous mortality ratios with no formal
analysis of what caused the heterogeneity. Recently, a
meta-analysis of mortality in PD has been published,
but this only included 8 studies and excluded retro-
spective studies and studies reporting unadjusted risk
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ratios or standardized mortality ratios (SMRs).6 Sev-
eral authors have stated that mortality from PD
reduced after the introduction of levodopa (L-dopa) in
the late 1960s.7-9 One review concluded that mortality
had reduced initially but that it subsequently increased
to a level similar to the pre–L-dopa era.1 However,
these observations were based only on one pre–L-dopa
study as the comparator,10 and those reviews, includ-
ing another pre–L-dopa study,11 have expressed uncer-
tainty about this.3,5
Given the absence of a comprehensive systematic
review and the ongoing uncertainty of the impact of
PD on mortality, we aimed to: 1) conduct a systematic
review of studies of mortality in PD; 2) perform meta-
analysis of mortality outcomes; 3) use meta-regression
to explore heterogeneity in mortality estimates; and 4)
describe which independent predictors of mortality
have been identified in previous studies.
Methods
Inclusion/Exclusion Criteria
We developed a protocol with predefined inclusion
and exclusion criteria (http://www.abdn.ac.uk/iahs/
documents/AM_Mortality_systematic_review_protocol.
pdf). We sought to include all observational studies of
mortality in PD, with follow-up of at least 1 year,
reporting quantitative measures of mortality (either
comparisons with a control population or survival in a
PD cohort) or post-mortem series reporting disease
duration at death. We excluded highly selected cohorts
(for example, only very-young-onset, demented, or sur-
gically treated patients); studies of parkinsonism in
general; studies in which the diagnosis of PD was
based on death certification (because it has low sensi-
tivity for detecting PD)12; and studies only published
in abstract form. We included studies of males only
and studies of only those aged older than 55 years or
older than 65 years (because these would include most
patients with PD)13 but excluded studies of only those
aged older than 70 years.
Literature Searches
We searched several electronic databases (MED-
LINE 1946 to 2012, Embase 1947 to 2012, CINAHL
1988 to 2012, and Web of Science 1970 to 2012,
last searched 12 October 2012) and reviewed refer-
ence lists of included studies and relevant reviews
identified in the search. The electronic searches used
keyword and free-text terms for PD combined with
terms for mortality or prognosis (see Supplemental
Data appendix 1). Electronic searches were validated
against hand searches of Movement Disorders and
Neurology from 2006 to 2010. Sensitivity and speci-
ficity were calculated using the hand searches as the
gold standard.
Assessment of Studies
References were downloaded to bibliographic soft-
ware and de-duplicated. Titles and abstracts of studies
identified from the search strategy were reviewed by 2
authors (A.D.M. and K.S.M.T.), and the full text of
potentially relevant articles was obtained. Foreign lan-
guage articles were translated using a translator or the
website translate.google.co.uk. We predefined a scale
to assess risk of bias in each study (see Supplemental
Data Appendix 2), but we have only reported 4 items
(representativeness of the cohort, adequate confirma-
tion of diagnosis, comparability of controls, and
excessive losses to follow-up), because the other items
(selection of control and reliability of outcome assess-
ment) scored a low risk of bias in all studies.
Data Extraction
Data on methodological features, demographic char-
acteristics, and mortality outcomes were extracted
from full-text articles to a paper data extraction form
by either A.D.M. or K.S.M.T., unblinded to study
details (blinding is time-consuming and only minimally
influences results).14 The data extraction from a subset
of studies was checked independently by C.E.C. Any
differences were resolved by discussion.
Statistical Analyses
Some data processing was necessary. Where possi-
ble, standard deviations were calculated from standard
errors; relative risks were calculated from counts of
deaths; median survival was measured from Kaplan-
Meier plots; and the confidence intervals (CIs) of
SMRs were calculated using Ury’s shortcut method.15
Meta-analyses on mortality ratios (SMRs and rela-
tive risks [RRs]) and time until death data were per-
formed using the DerSimonian and Laird random-
effects model.16 When mortality ratios were reported
at multiple times, we used the measurement nearest to
10 years. Meta-analysis of ratios was performed on a
logarithmic scale. The standard error of log(SMR) was
calculated thus:
SE logðSMRÞ ¼ logðupper limit 95%
CI=lower limit 95%CIÞ=3:92 (1)
17Studies were stratified into inception (i.e., all partici-
pants recruited at, or soon after, diagnosis) and non-
inception cohorts. Heterogeneity was assessed using
the I2 statistic.18 Small-study effects were assessed by
visual inspection of a funnel plot and Egger’s test.19
We used random-effects meta-regression to explore
prespecified demographic and study-quality variables
(as listed in Supplemental Data Table 3) that might
explain heterogeneity in the study estimates of mortal-
ity ratio using a residual maximum likelihood algo-
rithm.20 We also performed meta-regression analysis
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on mean time-to-death data in post-mortem studies.
We first performed univariable meta-regression and
then created a multivariable meta-regression model
using a backward stepwise method with a P-value of
0.1 as the cutoff for retention in the model, with a
Monte Carlo permutation to lower the possibility of
spurious results.20 We assessed the robustness of the
final model by re-running the model with each vari-
able removed in turn.
We plotted survival probability by follow-up dura-
tion and performed inverse-variance–weighted least
squares regression (variance calculated as p[1 – p]/n,
where p 5 proportion surviving and n 5 number in
the cohort) of survival probability on time, using the
latest measured survival in each study. We also plotted
survival probabilities within those studies that
reported survival at multiple follow-up times. Studies
restricted to older patients (cutoffs older than 55
years) were not included in analyses of survival proba-
bility, because older age groups have shorter survival.
We used descriptive statistics for median survival data
and assessed the effect of different baselines for mea-
surement (diagnosis, onset, or recruitment) with the
Wilcoxon rank-sum test. Prognostic factors reported
in individual studies were tabulated, including all fac-
tors examined for association with mortality (where
reported) and which of these were independently asso-
ciated with mortality. All statistical analyses were per-
formed using Stata version 12.1 (StataCorp LP,
College Station, TX, USA).
Results
Figure 1 shows the results of the searches. One fur-
ther study was identified from the validation hand-
searches. The overall sensitivity and specificity of the
electronic search strategy were 93% and 91%, respec-
tively. Eighty-eight studies were included in the review.
The methods of included studies are displayed in
Supplemental Data Table 1. Twenty studies were
inception cohorts, 56 were non-inception cohorts, and
12 were retrospective series of patients who had all
died (10 of which were autopsy series and 2 only con-
tained clinical data). Forty-seven studies were hospital
based, 24 were community based, 3 included separate
hospital- and community-based cohorts, 12 were trial-
based, and 2 did not specify. Four studies were carried
out in the pre–L-dopa period, and 8 straddled the
introduction of L-dopa. Sixty-eight studies only
included idiopathic PD, 5 also included a small pro-
portion of cases with post-encephalitic parkinsonism,
14 included other degenerative forms of parkinsonism
(older studies of PD before the importance of some
FIG. 1. Results of search strategy.
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atypical features was recognized and studies of parkin-
sonism based on coding for PD or pharmacy data
without validation of cases), and 1 did not state which
diagnoses were included but included only patients in
early trials of L-dopa. Many studies had exclusion cri-
teria relating to atypical features, but 12 had more
extensive exclusion criteria, predominantly relating to
co-morbid diseases. Six studies only included older
adults (older than 55 or older than 65), and 2 only
included men. Only 5 studies met all 4 quality criteria.
Sixteen studies met the representativeness criterion, 47
had adequate confirmation of diagnosis, 49 used com-
parable control comparators, and 54 had acceptable
losses to follow-up. Some studies with overlapping
groups of participants were included in the review (see
Supplemental Data Table 1), although no overlapping
studies were included in the same analysis. The results
of the included studies are displayed in Supplemental
Data Table 2.
Mortality Ratios
Forty-two studies were included in the meta-analysis
of mortality ratios (Fig. 2). The references for studies
FIG. 2. DerSimonian and Laird random effects meta-analysis of standardized mortality ratios and mortality risk ratios. The I2 statistic for heterogene-
ity for inception cohorts is 81.9% (P < 0.001), which reduces to 3.8% (P 5 0.40) if the study Hoehn 1967 is removed. The pooled mortality ratio for
inception cohorts excluding this study is 1.41 (95% CI, 1.28-1.55). A pooled estimate is not presented for non-inception cohorts, because heteroge-
neity is high (I2 5 95.1%, P < 0.001), and no single study is responsible for the heterogeneity. [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
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included in this and every other analysis are given in
Supplemental Data Appendix 3. The overall mortality
ratio in the inception cohorts (9 studies; 1,801
patients; median follow-up duration, 9 years) was
1.52 (95% CI, 1.25-1.78), but heterogeneity was high
(I2, 73.5%). Most of the heterogeneity was because of
a single study (Hoehn, 1967),10 and when this study
was removed, the overall mortality ratio was 1.41
(95% CI, 1.28-1.55) with low heterogeneity (I2,
3.8%). The non-inception cohorts (33 studies; 27,480
patients; median follow-up duration, 7 years) had
mortality ratios ranging from 0.90 to 3.79, with major
heterogeneity (I2, 95.1%) and no studies clearly driv-
ing the heterogeneity. Calculation of a pooled measure
of effect was therefore inappropriate. Repeating the
meta-analysis without the studies of only men or older
people did not significantly reduce the heterogeneity.
A funnel plot (Supplemental Data Figure 1) did not
show any evidence of publication bias or other small-
study effect (Egger’s test, P 5 0.87).
The results of univariable meta-regression analyses
on mortality ratios are shown in Supplemental Data
Table 3. Only time from recruitment to outcome mea-
surement was statistically significant, with mortality
ratios decreasing with longer follow-up. In the final
multivariable meta-regression model, inception
cohorts, measurements at longer follow-up duration,
older study recruitment year, and post–L-dopa studies
were associated with lower mortality ratios (Supple-
mental Data Table 4). The proportion of between-
study variance explained by the model was 33.7%,
but the residual heterogeneity was still very high
(91.9%). None of the variables in the multivariable
model was robust to the sensitivity analyses (Supple-
mental Data Table 5), and the L-dopa era variable in
particular was not robust, because only 2 pre–L-dopa
studies had heterogeneous mortality ratios.
Nine studies reported mortality ratios at multiple
times (Supplemental Data Fig. 2). Ratios increased
with longer follow-up in most of these studies. Seven-
teen studies reported mortality ratios by sex (approxi-
mately 3,340 mens and 2,190 women). Meta-analysis
of mortality ratios stratified by sex (Supplemental
Data Fig. 3) demonstrated major heterogeneity in
study estimates of mortality ratios in both men and
women (81.9% and 83.5%, respectively), so pooled
estimates were not presented. Univariable meta-
regression of sex on these data showed no significant
differences between males and females (P 5 0.17).
Survival
Forty-five studies (27,458 patients) reported survival
proportion at specific times (Fig. 3A). Where survival
was reported at multiple points in a study, only the
latest follow-up is shown. The regression coefficient
was –0.045 (95% CI, –0.056-0.033). Major heteroge-
neity was found between the studies, but, on average,
survival was reduced by approximately 5% per year
of follow-up. Nineteen studies reported survival at
multiple follow-up points (Fig. 3B). Despite marked
heterogeneity, the rates of decline in survival over
time seem to be approximately constant after the first
few years. Eighteen studies reported median survival,
5 inception and 13 non-inception cohorts (Supplemen-
tal Data Table 6), which ranged from 6 to 22 years.
Significant differences were found between studies
measuring survival from different baselines (from diag-
nosis, onset, or recruitment), but there were few stud-
ies in each group.
Disease Duration at Death
Meta-analysis of 10 studies (1,306 patients) report-
ing the mean disease duration at death (Fig. 4) showed
major heterogeneity (I2, 94.1%). Removing the 2 non-
autopsy studies only led to a minor reduction in heter-
ogeneity (I2, 92.1%). Univariable random-effects
meta-regression (Supplemental Data Table 7) showed
FIG. 3. Survival in Parkinson’s disease. A: The circles represent the
probability of survival at last follow-up in each of 45 studies report-
ing proportion surviving. Circle size represents study weight. The
red line is a line of best fit. B: Longitudinal survival probability in 19
studies reporting survival at multiple times. Each line represents an
individual study with markers indicating survival at specified times.
[Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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only one significant variable, age at diagnosis, but two
significant variables in the final multivariable model:
studies with earlier recruitment period (i.e., from lon-
ger ago) and increasing mean age at diagnosis were
associated with shorter disease duration (Supplemental
Data Table 8).
Prognostic Factors
Twenty-one studies reported independent predictors
of mortality, and these results can be found in full in
Supplemental Data Table 2. Table 1 presents frequen-
cies of studies that found the factors independently pre-
dictive. Several studies did not report negative findings,
so quantitative analysis of these data was not possible.
Discussion
Mortality ratios ranged widely, but almost all of the
studies showed increased mortality in PD. Most mortal-
ity ratios lay between 1.2 and 2.4, but, because of the
major heterogeneity in the included studies, calculation
of an overall measure was inappropriate. Inception
cohorts gave more reliable information and have a
pooled mortality ratio of approximately 1.5. Little of
the heterogeneity was explained by the meta-regression
analyses, doubtless because of the use of study-level
variables rather than individual-patient data. Mortality
ratios appear to increase with increased duration of
follow-up within studies. Major heterogeneity also was
found in the measures of survival studied, but survival
decreased on average by 5% per year, and the rate of
decline is approximately constant between studies. The
duration from disease onset to death in a series of
deceased patients ranged from 7 to 14 years, again with
major heterogeneity, some of which was explained by
year of study and age at diagnosis. Older age at onset
and the presence of dementia were most consistently
found to be independent predictors of mortality.
The results of the meta-regression analyses to
explore the heterogeneity in mortality estimates must
be regarded cautiously given that none of the variables
was robust to sensitivity analyses; the number of stud-
ies in the time-to-death analysis was small; and the
residual heterogeneity, after adjusting for the variables
in the meta-regression model, remained high. Addi-
tionally, the L-dopa–era variable was inherently non-
robust because the only 2 pre–L-dopa studies had
quite different results. We therefore do not think there
is good evidence that L-dopa has led to a reduction in
mortality in PD. Our data suggest that mortality ratios
in PD have increased over time, but why is unclear.
Perhaps life expectancy has risen more quickly in the
general population than in PD, rather than any
increase occurring in PD mortality.
Several methodological attributes of individual stud-
ies may introduce bias to reported mortality measures.
Major sources of bias include the use of non-inception
cohorts, which introduces selection biases, including a
survival bias (those with longer disease duration will
be more likely to be recruited)21,22; recruitment of
patients from hospital or specialist clinics only (older
people and those with lower socioeconomic status are
less likely to be referred)23; differences in diagnostic
accuracy (“possible” PD may have a higher mortality
rate than “definite” PD)24; exclusion of patients with,
for example, co-morbidities (leading to underestima-
tion of mortality ratios); or the use of noncomparable
controls (the use of healthier controls will overesti-
mate mortality ratios, for example). Measuring mor-
tality ratios or survival from disease onset rather than
diagnosis overestimates the time at risk as no deaths
in patients with PD before diagnosis will be detected
(an immortal time bias), thus underestimating
FIG. 4. Meta-analysis of time from disease onset or diagnosis to death in a retrospective series of deceased patients using a DerSimonian and Laird
random effects model. The I2 heterogeneity statistic is 97.4%: a pooled estimate is therefore not presented. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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mortality in PD,25-28 and patients’ recall of onset is
often unreliable. Other potential sources of bias
include retrospective data collection and high losses to
follow-up. Autopsy studies are particularly prone to
selection biases.
Specific factors relating to study design may con-
found the association between PD and mortality.
Increased life expectancy over time in the general pop-
ulation may influence survival rates, but the effect of
this on mortality ratios is unclear. Treatment also may
alter prognosis over time, but we did not find any
robust evidence that L-dopa has reduced mortality,
and we are not aware of data to suggest that any
other treatments alter survival. We have demonstrated
some empirical evidence that mortality ratios within
studies increase over longer durations of follow-up but
some weaker evidence of a trend in the opposite direc-
tion between studies.
This systematic review has several strengths. We
used a protocol with pre-specified plans for analysis,
performed comprehensive searches with broad inclu-
sion criteria, did not use language restrictions, and
assessed individual studies’ methodologies and results
thoroughly.
The main limitations of this review relate to the limi-
tation of the primary studies. As we have discussed,
several methodological limitations were present in
many of the studies that are associated with risk of
bias. A more detailed quality assessment scale may have
provided a more refined assessment of the risk of bias,
but given the generally poor quality on the crude scale
we used, a more sophisticated scale would be unlikely
to yield additional insights. Some studies reporting mor-
tality as a secondary outcome may have been missed in
the database searches. Additionally, variations in the
type of data reported and poor reporting of demo-
graphic, clinical, or methodological data in some studies
introduced reporting bias into this review. A major
limitation to our efforts to explore heterogeneity is the
use of study-level variables, because many factors that
influence variability within studies may not be apparent
at the study level (the “ecological fallacy”).29,30 Addi-
tionally, publication bias is likely in the reporting of
predictive factors of mortality, because several studies
only report positive findings. Most of the studies in this
review were from Europe or North America, so gener-
alizability to other geographical areas may be limited.
Another potential limitation is the combination of
different ratio measures in the meta-analyses.
Although this does introduce some heterogeneity, it is
preferable to excluding studies and thereby reducing
statistical power.31 Some authors have argued that
SMRs are inherently noncomparable, because large
differences in the age structure of populations may
introduce biases,32 but this is also true in comparisons
of studies with recruited controls, and significant var-
iations in age structures rarely occur in practice.33 In
any case, random-effects meta-analysis assumes inher-
ent non-comparability in the studies analyzed.34
In conclusion, PD is associated with increased mor-
tality, approximately 1.5 times the control mortality
in inception cohorts, and a decrease in survival of
approximately 5% per year of follow-up. However,
poor study quality and heterogeneity in study methods
and patients studied have hampered synthesis of mor-
tality data in this review. Further high-quality studies
of mortality need to be performed. We recommend
that these studies should, as a minimum: 1) be incep-
tion cohorts; 2) be community based; 3) have expert
confirmation of diagnosis using validated diagnostic
criteria; 4) have no exclusion criteria (other than those
relating to accuracy of diagnosis); 5) have prospective
follow-up; 6) measure long-term outcomes; and 7) use
diagnosis as a baseline for measurements. Several such
studies are underway.13,35-38 To maximize their poten-
tial value, individual-patient-data meta-analysis of
such studies could be performed. Additionally, the
data on prognostic factors from this review could be
used to guide the choice of predictors in the develop-
ment of prognostic models.
TABLE 1. Prognostic factors independently associated with mortality in two or more studies
Prognostic factor
Studies Reporting Factor Independ-
ently Associated With Increased Mor-
tality (N)/ Studies Which Examined
the Association (N) Referencesa
Increasing age (either at onset or recruitment) 15/17 2, 7, 16, 23, 24, 33, 34, 65, 75, 76, 78, 82, 85, 97, 105, 123, 125
Presence of dementia 9/13 2, 16, 23, 32, 34, 41, 75, 82, 85, 92, 105, 112, 125
Male sex 6/17 7, 16, 23, 32, 33, 34, 65, 75, 76, 78, 82, 85, 92, 97, 105, 123, 125
Higher Hoehn & Yahr stage 5/8 16, 24, 32, 82, 97, 105, 123, 125
PIGD phenotype, prominent bradykinesia
or lack of tremor
4/8 2, 7, 16, 23, 32, 65, 78, 97
Higher parkinsonian impairment score 3/6 16, 75, 82, 85, 92, 97
Presence of psychosis or hallucinations 2/4 16, 23, 75, 78
Presence of extensor plantar response 2/2 78, 97
PIGD, postural instability and gait difficulties.
aRefer to Supplemental Data references.
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